You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLansoprazole
Accession NumberDB00448  (APRD00077)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI's available.
Structure
Thumb
Synonyms
AG 1749
Bamalite
Lansoprazol
Lansoprazole
Lansoprazolum
Lanzol
Lanzopral
Lanzul
Limpidex
Monolitum
Ogastro
Opiren
Prevacid
External Identifiers
  • A 65006
  • AG 1749
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-lansoprazoleCapsule, delayed release15 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lansoprazoleCapsule, delayed release30 mgOralDominion Pharmacal2014-07-08Not applicableCanada
LansoprazoleCapsule, delayed release15 mgOralSanis Health Inc2010-11-23Not applicableCanada
LansoprazoleCapsule, delayed release30 mgOralDominion PharmacalNot applicableNot applicableCanada
LansoprazoleCapsule, delayed release15 mg/1OralSTAT Rx USA LLC2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralRebel Distributors Corp2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mgOralPharmascience Inc2015-02-11Not applicableCanada
LansoprazoleCapsule, delayed release30 mgOralSanis Health Inc2010-11-22Not applicableCanada
LansoprazoleCapsule, delayed release15 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
LansoprazoleCapsule, delayed release30 mg/1OralSTAT Rx USA LLC2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
LansoprazoleCapsule, delayed release30 mgOralPro Doc Limitee2011-06-07Not applicableCanada
LansoprazoleCapsule, delayed release30 mg/1Oralbryant ranch prepack2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralRebel Distributors Corp2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release15 mgOralPharmascience Inc2015-01-13Not applicableCanada
Lansoprazole-15Capsule, delayed release15 mgOralSivem Pharmaceuticals Ulc2014-10-102015-10-13Canada
Lansoprazole-30Capsule, delayed release30 mgOralSivem Pharmaceuticals Ulc2012-06-112015-10-13Canada
Mylan-lansoprazoleCapsule, delayed release15 mgOralMylan Pharmaceuticals Ulc2010-06-18Not applicableCanada
Mylan-lansoprazoleCapsule, delayed release30 mgOralMylan Pharmaceuticals Ulc2010-06-18Not applicableCanada
Ntp-lansoprazoleCapsule, delayed release15 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-lansoprazoleCapsule, delayed release30 mgOralTeva Canada LimitedNot applicableNot applicableCanada
PMS-lansoprazoleCapsule, delayed release15 mgOralPharmascience Inc2013-05-15Not applicableCanada
PMS-lansoprazoleCapsule, delayed release30 mgOralPharmascience Inc2013-05-15Not applicableCanada
PrevacidCapsule, delayed release30 mg/1OralPhysicians Total Care, Inc.2000-08-30Not applicableUs
PrevacidCapsule, delayed release30 mgOralTakeda Pharmaceuticals America Inc1995-12-31Not applicableCanada
PrevacidCapsule, delayed release30 mg/1Oralbryant ranch prepack1995-05-10Not applicableUs
PrevacidCapsule, delayed release15 mg/1OralTakeda Pharmaceuticals America, Inc.1995-05-10Not applicableUs
PrevacidTablet, orally disintegrating, delayed release30 mg/1OralPhysicians Total Care, Inc.2005-05-17Not applicableUs
PrevacidTablet, orally disintegrating, delayed release30 mg/1OralCardinal Health2002-08-30Not applicableUs
PrevacidCapsule, delayed release15 mg/1Oralbryant ranch prepack1995-05-10Not applicableUs
PrevacidCapsule, delayed release30 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1995-05-10Not applicableUs
PrevacidTablet, orally disintegrating, delayed release15 mg/1OralPhysicians Total Care, Inc.2007-07-11Not applicableUs
PrevacidCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2016-05-26Not applicableUs
PrevacidCapsule, delayed release15 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
PrevacidCapsule, delayed release30 mg/1OralPd Rx Pharmaceuticals, Inc.1995-05-10Not applicableUs
PrevacidCapsule, delayed release30 mg/1OralTakeda Pharmaceuticals America, Inc.1995-05-10Not applicableUs
PrevacidCapsule, delayed release15 mgOralTakeda Pharmaceuticals America Inc1995-12-31Not applicableCanada
Prevacid FastabTablet, delayed release15 mgOralTakeda Pharmaceuticals America Inc2006-11-24Not applicableCanada
Prevacid FastabTablet, delayed release30 mgOralTakeda Pharmaceuticals America Inc2005-12-01Not applicableCanada
Prevacid SolutabTablet, orally disintegrating, delayed release15 mg/1OralTakeda Pharmaceuticals America, Inc.2002-08-30Not applicableUs
Prevacid SolutabTablet, orally disintegrating, delayed release30 mg/1OralRebel Distributors Corp2002-08-30Not applicableUs
Prevacid SolutabTablet, orally disintegrating, delayed release30 mg/1OralTakeda Pharmaceuticals America, Inc.2002-08-30Not applicableUs
Q-lansoprazoleCapsule, delayed release15 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-lansoprazoleCapsule, delayed release30 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ran-lansoprazoleCapsule, delayed release30 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-lansoprazoleCapsule, delayed release15 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Riva-lansoprazoleCapsule, delayed release15 mgOralLaboratoire Riva Inc2014-06-12Not applicableCanada
Riva-lansoprazoleCapsule, delayed release30 mgOralLaboratoire Riva Inc2014-06-12Not applicableCanada
Sandoz LansoprazoleTablet30 mgOralSandoz Canada Incorporated2012-07-03Not applicableCanada
Sandoz LansoprazoleCapsule, delayed release15 mgOralSandoz Canada Incorporated2012-07-03Not applicableCanada
Teva-lansoprazoleCapsule, delayed release30 mgOralTeva Canada Limited2009-11-02Not applicableCanada
Teva-lansoprazoleCapsule, delayed release15 mgOralTeva Canada Limited2009-11-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lansoprazoleCapsule, delayed release30 mgOralApotex Inc2009-06-03Not applicableCanada
Apo-lansoprazoleCapsule, delayed release15 mgOralApotex Inc2009-06-03Not applicableCanada
LansoprazoleCapsule, delayed release15 mg/1OralWockhardt USA LLC.2012-08-10Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralAjanta Pharma Limited2016-10-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralActavis Inc2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWockhardt Limited2012-08-10Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
LansoprazoleCapsule, delayed release pellets30 mg/1OralAv Pak2016-07-14Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralTeva Pharmaceuticals Usa, Inc.2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralSandoz Inc2010-04-23Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2013-03-262016-04-05Us
LansoprazoleCapsule, delayed release30 mg/1OralPreferred Pharmaceuticals Inc.2015-09-11Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralUnit Dose Services2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2015-05-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralA S Medication Solutions2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralBlue Point Laboratories2013-12-01Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralA S Medication Solutions2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralRebel Distributors Corp2010-10-15Not applicableUs
LansoprazoleTablet, orally disintegrating, delayed release30 mg/1OralPhysicians Total Care, Inc.2010-11-30Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralPreferred Pharmaceuticals, Inc.2014-05-23Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1Oralbryant ranch prepack2013-08-23Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPreferred Pharmaceuticals Inc.2016-05-20Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralWockhardt USA LLC.2012-08-10Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralAjanta Pharma Limited2016-10-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralActavis Inc2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralWockhardt Limited2012-08-10Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1OralMylan Pharmaceuticals Inc.2009-11-10Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralProficient Rx LP2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralA S Medication Solutions2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralTeva Pharmaceuticals Usa, Inc.2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralSandoz Inc2010-04-23Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2013-07-09Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPreferred Pharmaceuticals, Inc.2013-06-04Not applicableUs
LansoprazoleCapsule, delayed release pellets30 mg/1OralMylan Institutional Inc.2009-12-01Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralDIRECT RX2014-01-01Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralA S Medication Solutions2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralBlue Point Laboratories2013-12-01Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralSterling Knight Pharmaceuticals Llc2016-10-31Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralAv Kare, Inc.2013-08-05Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralDr.Reddy's laboratories Ltd.2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPreferred Pharmaceuticals, Inc.2013-06-04Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-21Not applicableUs
LansoprazoleCapsule, delayed release pellets30 mg/1OralPreferred Pharmaceuticals Inc.2016-09-07Not applicableUs
LansoprazoleCapsule, delayed release pellets30 mg/1OralMylan Pharmaceuticals Inc.2009-11-10Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1OralCadila Healthcare Limited2013-08-23Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1OralDIRECT RX2014-01-01Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralSun Pharma Global FZE2013-09-16Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralAmerican Health Packaging2015-08-15Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralPhysicians Total Care, Inc.2009-11-17Not applicableUs
LansoprazoleCapsule, delayed release pellets30 mg/1OralPreferred Pharmaceuticals, Inc.2015-01-01Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralProficient Rx LP2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralAidarex Pharmaceuticals LLC2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralBreckenridge Pharmaceutical, Inc.2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralDIRECT RX2014-01-01Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralA S Medication Solutions2014-12-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralAmerican Health Packaging2010-09-15Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1OralZydus Pharmaceuticals (USA) Inc.2013-08-23Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1OralA S Medication Solutions2013-08-23Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralAv Kare, Inc.2013-08-05Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralDr.Reddy's laboratories Ltd.2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-21Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralSun Pharma Global FZE2013-09-16Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralAmerican Health Packaging2015-08-15Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralA S Medication Solutions2013-09-16Not applicableUs
LansoprazoleCapsule, delayed release pellets30 mg/1OralCadila Healthcare Limited2013-08-23Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralA S Medication Solutions2010-04-23Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralRebel Distributors Corp2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPhysicians Total Care, Inc.2010-11-17Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralPreferred Pharmaceuticals, Inc.2010-10-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1Oralbryant ranch prepack2012-08-07Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPreferred Pharmaceuticals Inc.2016-05-20Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralAmerican Health Packaging2010-09-152016-07-31Us
LansoprazoleCapsule, delayed release pellets30 mg/1OralZydus Pharmaceuticals (USA) Inc.2013-08-23Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralBreckenridge Pharmaceutical, Inc.2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
LansoprazoleCapsule, delayed release pellets15 mg/1OralAv Pak2016-07-14Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Berkley and Jensen LansoprazoleCapsule, delayed release15 mg/1OralBJWC2012-05-22Not applicableUs
Careone Acid ReducerCapsule, delayed release15 mg/1OralAmerican Sales Company2016-10-14Not applicableUs
Careone LansoprazoleCapsule, delayed release15 mg/1OralAmerican Sales Company2012-05-24Not applicableUs
Dg Health LansoprazoleCapsule, delayed release15 mg/1OralDolgencorp, LLC2012-05-21Not applicableUs
Equaline LansoprazoleCapsule, delayed release15 mg/1OralSupervalu Inc2012-05-21Not applicableUs
Equate Lansoprazole Delayed ReleaseCapsule, delayed release15 mg/1OralWal Mart Stores Inc2014-05-05Not applicableUs
Exchange Select LansoprazoleCapsule, delayed release15 mg/1OralArmy & Air Force Exchange Service2012-06-11Not applicableUs
Good Neighbor Pharmacy LansoprazoleCapsule, delayed release15 mg/1OralAmerisource Bergen2012-05-31Not applicableUs
Good Sense LansoprazoleCapsule, delayed release15 mg/1OralL. Perrigo Company2012-05-24Not applicableUs
Harris Teeter Acid ReducerCapsule, delayed release15 mg/1OralHarris Teeter, LLC2015-03-30Not applicableUs
Health Mart LansoprazoleCapsule, delayed release15 mg/1OralMc Kesson2012-05-21Not applicableUs
Healthy Accents LansoprazoleCapsule, delayed release15 mg/1OralDZA Brands LLC2012-05-18Not applicableUs
Heartburn Relief 24 HourCapsule, delayed release15 mg/1OralOUR FAMILY (Nash Finch Company)2013-03-27Not applicableUs
Kirkland Signature Lansoprazole Delayed ReleaseCapsule, delayed release15 mg/1OralCostco Wholesale Company2013-12-17Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralSafeway2014-10-07Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralChain Drug Consortium, LLC2012-07-06Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPerrigo New York Inc2012-08-07Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralP and L Development of New York Corporation2013-01-15Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralRugby Laboratories Inc2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralBest Choice (Valu Merchandisers Company)2012-04-30Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralRite Aid Corporation2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralThe Kroger Co.2012-09-01Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWestern Family Foods, Inc.2012-07-24Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralSIMPLY RIGHT (Sam's West, Inc.)2013-03-30Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralKroger Company2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralMeijer Distribution Inc2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWockhardt Limited2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralMajor Pharmaceuticals2012-03-29Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralPublix Super Markets Inc2012-08-10Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWestern Family Foods Inc2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWal Mart Stores Inc2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralShopko Stores Operating Co., LLC2013-06-05Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWalgreen Co2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralSafeway, Inc.2012-12-31Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralDr. Reddy's Laboratories Limited2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralWockhardt USA LLC.2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralCVS Pharmacy2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralFreds Inc2012-12-04Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralActavis Pharma, Inc.2016-07-22Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralH E B2012-05-18Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralHy Vee Inc2012-05-21Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralGericare Pharmaceuticals2013-04-25Not applicableUs
Lansoprazole Heartburn Relief 24 HourCapsule, delayed release15 mg/1OralQUALITY CHOICE (Chain Drug Marketing Association)2013-04-30Not applicableUs
Leader LansoprazoleCapsule, delayed release15 mg/1OralCardinal Health2012-05-30Not applicableUs
Members Mark LansoprazoleCapsule, delayed release15 mg/1OralSam's West Inc2015-07-16Not applicableUs
Preferred Plus LansoprazoleCapsule, delayed release15 mg/1OralKinray2014-06-09Not applicableUs
Prevacid 24 HrCapsule, delayed release15 mg/1OralGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2009-10-12Not applicableUs
Rugby Heartburn TreatmentCapsule, delayed release15 mg/1OralRugby Laboratories2014-05-05Not applicableUs
Shoprite LansoprazoleCapsule, delayed release15 mg/1OralWakefern Food Corporation2013-06-11Not applicableUs
Signature Care Acid ReducerCapsule, delayed release15 mg/1OralSafeway2015-09-27Not applicableUs
Simply Right LansoprazoleCapsule, delayed release15 mg/1OralSam's West Inc2014-05-29Not applicableUs
Smart Sense Acid ReducerCapsule, delayed release15 mg/1OralKmart Corporation2012-05-22Not applicableUs
Smart Sense LansoprazoleCapsule, delayed release15 mg/1OralKmart Corporation2015-12-28Not applicableUs
Sunmark LansoprazoleCapsule, delayed release15 mg/1OralMc Kesson2012-05-21Not applicableUs
Topcare LansoprazoleCapsule, delayed release15 mg/1OralTopco Associates LLC2012-09-10Not applicableUs
Up and Up LansoprazoleCapsule, delayed release15 mg/1OralTarget Corporation2012-05-18Not applicableUs
Well At Walgreens LansoprazoleCapsule, delayed release15 mg/1OralWalgreen Company2012-05-18Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AgoptonTakeda
BamaliteNot Available
LansolocCipla Medpro
LanzolCipla
LanzopralPharma Investi
LanzopranRanbaxy
LimpidexSigma-Tau
MonolitumSalvat
OgastTakeda
OgastroAbbott
OpirenAlmirall
Prevacid 24HRNovartis
Prevacid IVNovartis
ProsoganTakeda
TakepronTakeda
UlpaxHormona
ZoprolToprak
ZotonPfizer
Brand mixtures
NameLabellerIngredients
Hp-pacTakeda Pharmaceuticals America Inc
Lansoprazole, Amoxicillin, and ClarithromycinTeva Pharmaceuticals USA Inc
Lansoprazole, Amoxicillin, ClarithromycinCitron Pharma LLC
SaltsNot Available
Categories
UNII0K5C5T2QPG
CAS number103577-45-3
WeightAverage: 369.361
Monoisotopic: 369.075882012
Chemical FormulaC16H14F3N3O2S
InChI KeyMJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
IUPAC Name
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Structured Indications
PharmacodynamicsLansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.
Mechanism of actionLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium-transporting ATPase alpha chain 1Proteinyes
inhibitor
HumanP20648 details
Related Articles
AbsorptionThe absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation.

SubstrateEnzymesProduct
Lansoprazole
5-HydroxylansoprazoleDetails
Lansoprazole
Lansoprazole sulfoneDetails
Route of eliminationFollowing single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.
Half life1.5 (± 1.0) hours
ClearanceNot Available
ToxicitySymptoms of overdose include abdominal pain, nausea and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Lansoprazole Action PathwayDrug actionSMP00227
Lansoprazole Metabolism PathwayDrug metabolismSMP00614
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4986893 CYP2C19*3A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Lansoprazole can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Lansoprazole.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Lansoprazole.Approved
AcetaminophenThe serum concentration of Lansoprazole can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Lansoprazole.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lansoprazole.Approved
AlbendazoleThe serum concentration of Lansoprazole can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Lansoprazole can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Lansoprazole can be increased when it is combined with Alectinib.Approved
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.Approved
AlfentanilThe serum concentration of Lansoprazole can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Lansoprazole.Approved, Investigational
AmantadineThe serum concentration of Lansoprazole can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Lansoprazole.Approved, Investigational
Aminohippuric acidThe serum concentration of Lansoprazole can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Lansoprazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Lansoprazole.Approved
AmlodipineThe serum concentration of Lansoprazole can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Lansoprazole.Approved
AmphetamineLansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
AmprenavirThe serum concentration of Lansoprazole can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Lansoprazole can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lansoprazole.Approved
AprepitantThe serum concentration of Lansoprazole can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
ArmodafinilThe metabolism of Lansoprazole can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Lansoprazole.Approved, Investigational
AstemizoleThe serum concentration of Lansoprazole can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Lansoprazole.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Lansoprazole.Approved
AtomoxetineThe metabolism of Lansoprazole can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Lansoprazole can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Lansoprazole.Approved, Investigational
AzelastineThe serum concentration of Lansoprazole can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Lansoprazole can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Lansoprazole can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Lansoprazole can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Lansoprazole.Approved, Vet Approved
BexaroteneThe serum concentration of Lansoprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Lansoprazole can be increased when it is combined with Biperiden.Approved
BoceprevirThe metabolism of Lansoprazole can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Lansoprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Lansoprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lansoprazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lansoprazole.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Lansoprazole.Approved, Investigational
BuprenorphineThe serum concentration of Lansoprazole can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Lansoprazole can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Lansoprazole.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Lansoprazole.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Lansoprazole.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Lansoprazole.Approved
CandesartanThe serum concentration of Lansoprazole can be increased when it is combined with Candesartan.Approved
CapecitabineThe metabolism of Lansoprazole can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Lansoprazole can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Lansoprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Lansoprazole.Approved
CarvedilolThe serum concentration of Lansoprazole can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Lansoprazole can be increased when it is combined with Caspofungin.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Lansoprazole.Approved
CelecoxibThe metabolism of Lansoprazole can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Lansoprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lansoprazole.Withdrawn
ChloramphenicolThe metabolism of Lansoprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Lansoprazole can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Lansoprazole can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Lansoprazole can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Lansoprazole can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Lansoprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Lansoprazole can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Lansoprazole can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Lansoprazole can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Lansoprazole.Approved
CimetidineThe serum concentration of Lansoprazole can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Lansoprazole can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Lansoprazole.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Lansoprazole.Approved
ClarithromycinThe metabolism of Lansoprazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Lansoprazole can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Lansoprazole.Approved, Illicit
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Lansoprazole.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Lansoprazole can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Lansoprazole.Approved, Investigational
ClomipramineThe serum concentration of Lansoprazole can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Lansoprazole.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Lansoprazole resulting in a loss in efficacy.Approved, Nutraceutical
ClotrimazoleThe metabolism of Lansoprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Lansoprazole.Approved
CobicistatThe metabolism of Lansoprazole can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lansoprazole.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lansoprazole.Approved
ColforsinThe serum concentration of Lansoprazole can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Lansoprazole can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lansoprazole.Approved
CrizotinibThe metabolism of Lansoprazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Lansoprazole can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Lansoprazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Lansoprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lansoprazole.Approved
DabrafenibThe serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Lansoprazole can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Lansoprazole can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Lansoprazole.Approved
DarunavirThe metabolism of Lansoprazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
DaunorubicinThe serum concentration of Lansoprazole can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Lansoprazole.Approved
DeferasiroxThe serum concentration of Lansoprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lansoprazole.Approved
DesipramineThe serum concentration of Lansoprazole can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Lansoprazole can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Lansoprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmethylphenidateLansoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineLansoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DextromethorphanThe serum concentration of Lansoprazole can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Lansoprazole.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Lansoprazole can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Lansoprazole.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lansoprazole.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Lansoprazole.Approved
DigoxinThe serum concentration of Lansoprazole can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Lansoprazole can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Lansoprazole.Illicit
DiltiazemThe metabolism of Lansoprazole can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Lansoprazole can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Lansoprazole.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lansoprazole.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Lansoprazole can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Lansoprazole can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lansoprazole.Approved, Investigational
DoxorubicinThe serum concentration of Lansoprazole can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Lansoprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Lansoprazole can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Lansoprazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lansoprazole.Approved
EfavirenzThe serum concentration of Lansoprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Lansoprazole can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Lansoprazole.Approved, Investigational
EnalaprilThe serum concentration of Lansoprazole can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Lansoprazole can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Lansoprazole.Approved, Investigational
ErgonovineThe serum concentration of Lansoprazole can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Lansoprazole can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
ErythromycinThe metabolism of Lansoprazole can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Lansoprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Lansoprazole can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Lansoprazole.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Lansoprazole can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Lansoprazole can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Lansoprazole can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lansoprazole.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Lansoprazole.Withdrawn
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Lansoprazole.Approved
EtoposideThe serum concentration of Lansoprazole can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Lansoprazole can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Lansoprazole.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Lansoprazole.Approved
FelodipineThe serum concentration of Lansoprazole can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Lansoprazole can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseLansoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateLansoprazole can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateLansoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lansoprazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Lansoprazole.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Lansoprazole.Approved
FloxuridineThe metabolism of Lansoprazole can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fluconazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Lansoprazole.Investigational
FluorouracilThe metabolism of Lansoprazole can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Lansoprazole can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Lansoprazole can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Lansoprazole can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Lansoprazole can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Lansoprazole.Approved
FluvastatinThe metabolism of Lansoprazole can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Lansoprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Lansoprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lansoprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Lansoprazole can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Lansoprazole can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Lansoprazole.Approved
GemfibrozilThe metabolism of Lansoprazole can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Lansoprazole can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Lansoprazole can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Lansoprazole can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Lansoprazole can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Lansoprazole.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Lansoprazole.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Lansoprazole.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Lansoprazole.Approved, Vet Approved
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Lansoprazole.Approved
IdelalisibThe serum concentration of Lansoprazole can be increased when it is combined with Idelalisib.Approved
ImatinibLansoprazole may increase the dermatologic adverse activities of Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Lansoprazole.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Lansoprazole.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Lansoprazole.Approved
IndomethacinThe serum concentration of Lansoprazole can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe metabolism of Lansoprazole can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Lansoprazole.Approved, Investigational
IronLansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranLansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateLansoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Lansoprazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Lansoprazole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Lansoprazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
IvacaftorThe serum concentration of Lansoprazole can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Lansoprazole.Approved, Vet Approved
KetamineThe serum concentration of Lansoprazole can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Lansoprazole.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
KetoconazoleThe metabolism of Lansoprazole can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Lansoprazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lansoprazole can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Lansoprazole.Approved
LeflunomideThe metabolism of Lansoprazole can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Lansoprazole.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Lansoprazole.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Lansoprazole.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Lansoprazole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Lansoprazole.Approved
LevothyroxineThe serum concentration of Lansoprazole can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Lansoprazole can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Lansoprazole.Approved
LiothyronineThe serum concentration of Lansoprazole can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Lansoprazole can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Lansoprazole can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Lansoprazole can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Lansoprazole.Approved
LopinavirThe metabolism of Lansoprazole can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Lansoprazole can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Lansoprazole.Approved
LovastatinThe metabolism of Lansoprazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Lansoprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lansoprazole can be increased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Lansoprazole.Approved, Investigational
MaprotilineThe serum concentration of Lansoprazole can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Lansoprazole can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Lansoprazole can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Lansoprazole can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Lansoprazole can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Lansoprazole.Approved
MethadoneThe serum concentration of Lansoprazole can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lansoprazole.Approved
MethylphenidateLansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Lansoprazole.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lansoprazole.Approved, Investigational
MibefradilThe serum concentration of Lansoprazole can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Lansoprazole can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Lansoprazole can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Lansoprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Lansoprazole.Approved
MitomycinThe serum concentration of Lansoprazole can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Lansoprazole can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Lansoprazole can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Lansoprazole can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Lansoprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Lansoprazole.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lansoprazole.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Lansoprazole.Approved
NafcillinThe serum concentration of Lansoprazole can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Lansoprazole.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Lansoprazole.Approved, Vet Approved
NaltrexoneThe serum concentration of Lansoprazole can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Lansoprazole can be increased when it is combined with Naringenin.Experimental
NefazodoneThe metabolism of Lansoprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy.Approved
NeostigmineThe serum concentration of Lansoprazole can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Lansoprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Lansoprazole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Lansoprazole can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Lansoprazole can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lansoprazole.Approved
NisoldipineThe serum concentration of Lansoprazole can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Lansoprazole can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Lansoprazole.Approved
NorethisteroneThe serum concentration of Lansoprazole can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Lansoprazole.Approved, Investigational
OlaparibThe metabolism of Lansoprazole can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Lansoprazole.Approved
OmeprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Lansoprazole can be increased when it is combined with Osimertinib.Approved
P-NitrophenolThe serum concentration of Lansoprazole can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Lansoprazole can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Lansoprazole can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Lansoprazole can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Lansoprazole.Approved, Investigational
PantoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Lansoprazole can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Lansoprazole.Approved
PentobarbitalThe metabolism of Lansoprazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Lansoprazole can be increased when it is combined with Perindopril.Approved
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Lansoprazole.Approved
PhenobarbitalThe metabolism of Lansoprazole can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Lansoprazole.Approved
PhenytoinThe metabolism of Lansoprazole can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Lansoprazole can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Lansoprazole can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Lansoprazole.Approved
Platelet Activating FactorThe serum concentration of Lansoprazole can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Lansoprazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Lansoprazole.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Lansoprazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Lansoprazole.Approved
PrazosinThe serum concentration of Lansoprazole can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lansoprazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Lansoprazole.Approved, Vet Approved
PrimidoneThe metabolism of Lansoprazole can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lansoprazole can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Lansoprazole can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Lansoprazole can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Lansoprazole can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Lansoprazole.Approved, Investigational
ProtriptylineThe serum concentration of Lansoprazole can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lansoprazole.Approved
PyrimethamineThe metabolism of Lansoprazole can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Lansoprazole can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Lansoprazole.Approved
QuinacrineThe serum concentration of Lansoprazole can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Lansoprazole can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Lansoprazole can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Lansoprazole can be decreased when combined with Rabeprazole.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Lansoprazole.Approved
RanitidineThe serum concentration of Lansoprazole can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Lansoprazole.Approved, Investigational
ReboxetineThe serum concentration of Lansoprazole can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Lansoprazole can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Lansoprazole can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Lansoprazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Lansoprazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Lansoprazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lansoprazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Lansoprazole.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Lansoprazole.Approved
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Lansoprazole.Approved, Investigational
RitonavirThe metabolism of Lansoprazole can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Lansoprazole.Approved
RolapitantThe serum concentration of Lansoprazole can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Lansoprazole.Approved, Investigational
RosiglitazoneThe metabolism of Lansoprazole can be decreased when combined with Rosiglitazone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Lansoprazole.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Lansoprazole.Approved
ScopolamineThe serum concentration of Lansoprazole can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Lansoprazole can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Lansoprazole can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Lansoprazole.Approved
SertralineThe serum concentration of Lansoprazole can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Lansoprazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lansoprazole.Approved
SiltuximabThe serum concentration of Lansoprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lansoprazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Lansoprazole can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Lansoprazole can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Lansoprazole.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Lansoprazole.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Lansoprazole.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Lansoprazole.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Lansoprazole.Experimental
SpironolactoneThe serum concentration of Lansoprazole can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Lansoprazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Lansoprazole can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Lansoprazole can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Lansoprazole can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Lansoprazole can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Lansoprazole can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Lansoprazole can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Lansoprazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Lansoprazole can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Lansoprazole can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Lansoprazole can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.Approved, Investigational
TacrolimusThe serum concentration of Lansoprazole can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Lansoprazole can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Lansoprazole.Experimental
Technetium tc 99m etidronateThe therapeutic efficacy of Technetium tc 99m etidronate can be decreased when used in combination with Lansoprazole.Approved
Technetium Tc-99m MedronateThe therapeutic efficacy of Technetium Tc-99m Medronate can be decreased when used in combination with Lansoprazole.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lansoprazole.Approved
TelaprevirThe metabolism of Lansoprazole can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Lansoprazole can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Lansoprazole can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Lansoprazole.Approved
TerazosinThe serum concentration of Lansoprazole can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Lansoprazole can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe metabolism of Lansoprazole can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Lansoprazole can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Lansoprazole can be increased when it is combined with Testosterone.Approved, Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lansoprazole.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Lansoprazole.Approved
TiclopidineThe metabolism of Lansoprazole can be decreased when combined with Ticlopidine.Approved
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Lansoprazole.Approved, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Lansoprazole.Approved
TipranavirThe serum concentration of Lansoprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Lansoprazole can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Lansoprazole.Approved
TopiramateThe metabolism of Lansoprazole can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lansoprazole.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Lansoprazole.Approved, Investigational
TranylcypromineThe metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Lansoprazole.Approved
TrazodoneThe serum concentration of Lansoprazole can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Lansoprazole can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Lansoprazole can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Lansoprazole can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Lansoprazole can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Lansoprazole can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lansoprazole.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Lansoprazole.Approved
Valproic AcidThe metabolism of Lansoprazole can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Lansoprazole can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Lansoprazole.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Lansoprazole.Approved
VenlafaxineThe metabolism of Lansoprazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Lansoprazole can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Lansoprazole can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lansoprazole.Approved, Investigational
VincristineThe serum concentration of Lansoprazole can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Lansoprazole can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Lansoprazole.Approved
VoriconazoleThe serum concentration of Lansoprazole can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Lansoprazole.Approved
ZafirlukastThe metabolism of Lansoprazole can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Lansoprazole.Approved
ZimelidineThe serum concentration of Lansoprazole can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Lansoprazole can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Lansoprazole.Approved
Food Interactions
  • Avoid alcohol.
  • Food reduces bioavailabilty, but this has very little clinical impact.
  • Take 30-60 minutes before meals.
References
Synthesis Reference

Clarke Slemon, Bob Macel, “Preparation of omeprazole and lansoprazole.” U.S. Patent US5374730, issued December, 1986.

US5374730
General ReferencesNot Available
External Links
ATC CodesA02BD10A02BC53A02BC03A02BD03A02BD02A02BD07A02BD09
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7007
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.547
P-glycoprotein inhibitor IInhibitor0.5357
P-glycoprotein inhibitor IINon-inhibitor0.8692
Renal organic cation transporterInhibitor0.5521
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateNon-substrate0.8659
CYP450 3A4 substrateSubstrate0.6771
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8768
Ames testNon AMES toxic0.5858
CarcinogenicityNon-carcinogens0.7944
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8777
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Matrix laboratories ltd
  • Teva pharmaceuticals usa
  • Takeda pharmaceuticals north america inc
  • Novartis consumer health inc
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral15 mg/1
Capsule; capsule, extended release; kit; tabletOral
Capsule, delayed releaseOral30 mg/1
Capsule, delayed release pelletsOral15 mg/1
Capsule, delayed release pelletsOral30 mg/1
Kit
Capsule, delayed releaseOral15 mg
Capsule, delayed releaseOral30 mg
Tablet, orally disintegrating, delayed releaseOral15 mg/1
Tablet, delayed releaseOral15 mg
Tablet, delayed releaseOral30 mg
Tablet, orally disintegrating, delayed releaseOral30 mg/1
TabletOral30 mg
Prices
Unit descriptionCostUnit
Prevacid SoluTab 100 15 mg Dispersible Tablet Box620.65USD box
Prevacid NapraPAC 84 15-500 mg Kit Box175.8USD box
Prevpac Miscellaneous32.02USD ea
Prevpac patient pack28.22USD each
Lansoprazole 100% powder27.54USD g
Prevacid iv 30 mg vial27.31USD vial
Prevacid dr 15 mg capsule6.25USD capsule
Prevacid SoluTab 30 mg Dispersible Tablet6.21USD dispersible tablet
Prevacid 15 mg capsule dr6.0USD capsule
Prevacid 30 mg capsule dr6.0USD capsule
Prevacid dr 30 mg capsule5.91USD capsule
Lansoprazole 15 mg Delayed Release Capsule5.9USD capsule
Lansoprazole 30 mg Delayed Release Capsule5.9USD capsule
Prevacid 15 mg solutab5.73USD tablet
Prevacid 30 mg solutab5.73USD tablet
Lansoprazole dr 15 mg capsule5.67USD capsule
Lansoprazole dr 30 mg capsule5.67USD capsule
Prevacid 30 mg Delayed Release Capsule4.45USD capsule
Prevacid 15 mg Delayed Release Capsule4.32USD capsule
Apo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Apo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Prevacid 24hr dr 15 mg capsule0.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1327010 No1994-02-152011-02-15Canada
CA2419067 No2008-12-232021-08-17Canada
US4628098 No1992-11-102009-11-10Us
US6328994 Yes1999-11-172019-11-17Us
US7396841 Yes2002-02-172022-02-17Us
US7399485 Yes1998-11-262018-11-26Us
US7431942 Yes1999-11-172019-11-17Us
US7875292 Yes1999-11-172019-11-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178-182 °CNot Available
water solubility0.97 mg/LNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.25 mg/mLALOGPS
logP2.84ALOGPS
logP3.03ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.87 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.61 m3·mol-1ChemAxon
Polarizability34.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0udi-0090000000-502b719a981f262577baView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0uxr-0890000000-2734547f6dc584ba4877View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-053i-0930000000-94e6e179919ee803d567View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Matheson AJ, Jarvis B: Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61(12):1801-33. [PubMed:11693467 ]
  2. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997 Sep;54(3):473-500. [PubMed:9279507 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010 ]
  2. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. doi: 10.1007/s00228-009-0625-8. Epub 2009 Feb 24. [PubMed:19238367 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54